Plasma Cell Disorders
Conditions
Keywords
registry, plasma cell disorder
Brief summary
The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are: * The incidence of plasma cell disorders both before and after malignancy * Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) * Progression free survival (PFS) * overall survival * factors influencing overall survival, progression-free survival, and time to progression * Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. * genetic characteristics of plasma cell disorder * cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
Interventions
None listed
Sponsors
Siriraj Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014 * Aged 18 years and above
Exclusion criteria
* insufficient data needed for analysis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| register the plasma cell disorder patients | 10 years | register the plasma cell disorder patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence of plasma cell disorders | 10 years | incidence of plasma cell disorders both before and after malignancy |
| Time to progression | 10 years | \- Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) |
| Progression free survival | 10 years | Progression free survival |
| overall survival | 10 years | overall survival |
| influencing factors | 10 years | factors influencing overall survival, progression-free survival, and time to progression |
| Symptoms and signs | 10 years | Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients |
| genetic characteristics | 10 years | genetic characteristics of plasma cell disorder |
| cost-effectiveness | 10 years | cost-effectiveness of treatment in Thailand |
Contacts
Primary ContactChutima Kunacheewa, MD
Backup ContactWeerapat Owatthanapanich, MD
Outcome results
None listed